Taylor Samuel J, Langdon Wallace Y
Department of Pathology and Laboratory Medicine, School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.
Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.
Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
骨髓抑制是化疗最严重且具有限制性的副作用之一。我们最近的研究概述了一种通过给予初始剂量的FMS样酪氨酸激酶3（FLT3）抑制剂奎扎替尼来预防化疗诱导的骨髓抑制的策略。此外，通过连续给予经奎扎替尼预处理的氟尿嘧啶（5-FU）注射，我们在两种奎扎替尼耐药的急性髓系白血病（AML）小鼠模型中证明了一种消除疾病的新颖且有效的策略。
